Position in SYRE
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$3,769,421
New position
Shares Held
42,458
first reported quarter
Ownership
0.049%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#2
of 24 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 44%
Shared 39%
None 18%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Moody Aldrich Partners LLC holds $91,411,685 across 28 Biotechnology names. SYRE ranks #10 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ORKA |
Oruka Therapeutics, Inc.
|
101,411 | $9,651,284 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
28,160 | $8,901,094 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
59,601 | $7,305,890 | |
| 4 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
74,552 | $7,267,328 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
19,066 | $6,383,106 | |
| 6 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
146,077 | $5,466,201 | |
| 7 | NKTR |
Nektar Therapeutics
|
64,135 | $4,477,264 | |
| 8 | CAPR |
Capricor Therapeutics, Inc.
|
177,754 | $4,280,316 |
All Filings in SYRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,769,421 | 42,458 | Shares | Sole | 2026-07-15 | |
| No filing history on record for this holder in this stock. | ||||||